Symbols / SBFM
SBFM Chart
About
Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 5.74M |
| Enterprise Value | -2.70M | Income | -5.99M | Sales | 37.32M |
| Book/sh | 5.31 | Cash/sh | 1.90 | Dividend Yield | — |
| Payout | 0.00% | Employees | 52 | IPO | — |
| P/E | 0.22 | Forward P/E | 0.01 | PEG | — |
| P/S | 0.15 | P/B | 0.22 | P/C | — |
| EV/EBITDA | 0.59 | EV/Sales | -0.07 | Quick Ratio | 2.02 |
| Current Ratio | 4.21 | Debt/Eq | 3.53 | LT Debt/Eq | — |
| EPS (ttm) | 5.31 | EPS next Y | 199.80 | EPS Growth | — |
| Revenue Growth | 11.60% | Earnings | 2025-11-13 16:00 | ROA | -9.87% |
| ROE | -24.34% | ROIC | — | Gross Margin | 33.01% |
| Oper. Margin | -5.65% | Profit Margin | -16.06% | Shs Outstand | 4.91M |
| Shs Float | 4.90M | Short Float | 5.74% | Short Ratio | 6.97 |
| Short Interest | — | 52W High | 3.90 | 52W Low | 1.15 |
| Beta | 1.55 | Avg Volume | 43.85K | Volume | 21.86K |
| Target Price | $6.00 | Recom | None | Prev Close | $1.15 |
| Price | $1.17 | Change | 1.74% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$6.00
Mean price target
2. Current target
$1.17
Latest analyst target
3. DCF / Fair value
$-23.85
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.17
Low
$6.00
High
$6.00
Mean
$6.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-10-08 | reit | Aegis Capital | Buy → Buy | $7 |
| 2024-12-05 | reit | Aegis Capital | Buy → Buy | $15 |
| 2023-08-07 | init | Aegis Capital | — → Buy | $3 |
- $9.41M Q2 Revenue: Sunshine Biopharma Adds $5M Digital Asset and Reports Q1 $8.9M - Stock Titan ue, 14 Oct 2025 07
- Sunshine Biopharma Shareholders Approve Potential Reverse Stock Split - TipRanks Fri, 20 Feb 2026 21
- Sunshine Biopharma board authorized to consider reverse stock split By Investing.com - Investing.com Nigeria Fri, 20 Feb 2026 21
- Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM) - Yahoo Finance ue, 28 Oct 2025 07
- Sunshine Bio (NASDAQ: SBFM) gains Health Canada approval for Domperidone in $1.36B market - Stock Titan ue, 28 Oct 2025 07
- Sunshine Biopharma Reports 5.5x Revenue Increase: A Detailed Analysis - Meyka Wed, 01 Oct 2025 07
- Sunshine Biopharma stock soars after launch of cholesterol drug Pravastatin - Investing.com hu, 16 Oct 2025 07
- Sunshine Biopharma’s Meteoric Rise: Buy Opportunity? - StocksToTrade hu, 16 Oct 2025 07
- Sunshine Biopharma’s Leap: Analyzing Key Developments - timothysykes.com hu, 16 Oct 2025 07
- 10/20/40 mg Pravastatin launch: Sunshine Biopharma's generic Pravachol® in Canada, 100-tablet - Stock Titan hu, 16 Oct 2025 07
- Sunshine Biopharma Announces Sudden Resignation of Chief Operating Officer - TipRanks hu, 05 Feb 2026 08
- Sunshine Biopharma board authorized to consider reverse stock split - Investing.com Australia Fri, 20 Feb 2026 21
- Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules - Yahoo Finance Wed, 02 Apr 2025 07
- Sunshine Biopharma stock rises after Health Canada approval for Domperidone - Investing.com ue, 28 Oct 2025 07
- Doxycycline 100 mg now nationwide — Sunshine Biopharma launches generic antibiotic in Canada - Stock Titan Mon, 20 Oct 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -1.94K | -51.45 | -3.85M | 0.00 |
| TaxRateForCalcs | 0.04 | 0.21 | 0.21 | 0.00 |
| NormalizedEBITDA | -5.09M | -3.82M | -8.13M | -2.43M |
| TotalUnusualItems | -44.08K | -245.00 | -18.32M | -9.67M |
| TotalUnusualItemsExcludingGoodwill | -44.08K | -245.00 | -18.32M | -9.67M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -5.13M | -4.51M | -26.74M | -12.44M |
| ReconciledDepreciation | 223.53K | 149.15K | 25.16K | 12.74K |
| ReconciledCostOfRevenue | 24.20M | 15.75M | 2.65M | 117.83K |
| EBITDA | -5.14M | -3.82M | -26.45M | -12.09M |
| EBIT | -5.36M | -3.97M | -26.47M | -12.11M |
| NetInterestIncome | 487.23K | 674.67K | 479.24K | -328.82K |
| InterestExpense | 8.77K | 137.31K | 39.41K | 328.82K |
| InterestIncome | 496.00K | 811.97K | 518.65K | 0.00 |
| NormalizedIncome | -5.09M | -4.51M | -12.27M | -2.77M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -5.13M | -4.51M | -26.74M | -12.44M |
| TotalExpenses | 40.69M | 28.88M | 13.02M | 2.67M |
| TotalOperatingIncomeAsReported | -5.81M | -4.79M | -27.00M | -2.44M |
| DilutedAverageShares | 701.75K | 12.82K | 7.59K | 1.31K |
| BasicAverageShares | 701.75K | 12.82K | 7.59K | 1.31K |
| DilutedEPS | -7.32 | -351.36 | -3.52K | -9.52K |
| BasicEPS | -7.32 | -351.36 | -3.52K | -9.52K |
| DilutedNIAvailtoComStockholders | -5.13M | -4.51M | -26.74M | -12.44M |
| NetIncomeCommonStockholders | -5.13M | -4.51M | -26.74M | -12.44M |
| NetIncome | -5.13M | -4.51M | -26.74M | -12.44M |
| NetIncomeIncludingNoncontrollingInterests | -5.13M | -4.51M | -26.74M | -12.44M |
| NetIncomeContinuousOperations | -5.13M | -4.51M | -26.74M | -12.44M |
| TaxProvision | -234.86K | 395.17K | 233.30K | 0.00 |
| PretaxIncome | -5.37M | -4.11M | -26.51M | -12.44M |
| OtherIncomeExpense | -44.08K | -245.00 | -18.32M | -9.67M |
| SpecialIncomeCharges | 0.00 | -18.32M | -9.67M | |
| OtherSpecialCharges | -10.85K | 9.67M | ||
| ImpairmentOfCapitalAssets | 0.00 | 18.33M | 0.00 | |
| GainOnSaleOfSecurity | -44.08K | -245.00 | -476.00 | 50.00 |
| NetNonOperatingInterestIncomeExpense | 487.23K | 674.67K | 479.24K | -328.82K |
| InterestExpenseNonOperating | 8.77K | 137.31K | 39.41K | 328.82K |
| InterestIncomeNonOperating | 496.00K | 811.97K | 518.65K | 0.00 |
| OperatingIncome | -5.81M | -4.79M | -8.67M | -2.44M |
| OperatingExpense | 16.48M | 13.12M | 10.37M | 2.55M |
| OtherTaxes | 387.00K | 289.74K | 55.23K | 0.00 |
| DepreciationAmortizationDepletionIncomeStatement | 223.53K | 149.15K | 25.16K | 12.74K |
| DepreciationAndAmortizationInIncomeStatement | 223.53K | 149.15K | 25.16K | 12.74K |
| DepreciationIncomeStatement | 12.74K | |||
| ResearchAndDevelopment | 933.90K | 1.86M | 811.86K | 672.21K |
| SellingGeneralAndAdministration | 14.94M | 10.83M | 9.48M | 1.87M |
| SellingAndMarketingExpense | 940.28K | 734.25K | 578.09K | 0.00 |
| GeneralAndAdministrativeExpense | 14.00M | 10.10M | 8.90M | 1.87M |
| OtherGandA | 5.88M | 3.98M | 2.55M | 650.47K |
| SalariesAndWages | 8.12M | 6.11M | 6.35M | 1.22M |
| GrossProfit | 10.67M | 8.34M | 1.70M | 110.60K |
| CostOfRevenue | 24.20M | 15.75M | 2.65M | 117.83K |
| TotalRevenue | 34.87M | 24.09M | 4.35M | 228.43K |
| OperatingRevenue | 34.87M | 24.09M | 4.35M | 228.43K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 2.58M | 14.01K | 11.29K | 1.29K |
| ShareIssued | 2.58M | 14.01K | 11.29K | 1.29K |
| TotalDebt | 952.48K | 657.71K | 765.26K | 1.90M |
| TangibleBookValue | 20.47M | 19.76M | 20.85M | 111.66K |
| InvestedCapital | 23.49M | 21.21M | 21.63M | 2.01M |
| WorkingCapital | 19.65M | 19.34M | 20.38M | 2.10M |
| NetTangibleAssets | 20.48M | 19.76M | 20.85M | 211.66K |
| CapitalLeaseObligations | 952.48K | 657.71K | 765.26K | 0.00 |
| CommonStockEquity | 23.49M | 21.21M | 21.63M | 111.66K |
| PreferredStockEquity | 13.00K | 1.00K | 1.00K | 100.00K |
| TotalCapitalization | 23.50M | 21.21M | 21.63M | 2.11M |
| TotalEquityGrossMinorityInterest | 23.50M | 21.21M | 21.63M | 211.66K |
| StockholdersEquity | 23.50M | 21.21M | 21.63M | 211.66K |
| GainsLossesNotAffectingRetainedEarnings | -829.96K | 696.11K | 161.85K | -23.14K |
| OtherEquityAdjustments | -829.96K | 696.11K | 161.85K | -23.14K |
| RetainedEarnings | -69.04M | -63.91M | -59.40M | -32.66M |
| AdditionalPaidInCapital | 93.35M | 84.42M | 80.84M | 32.79M |
| CapitalStock | 15.58K | 1.01K | 23.59K | 102.59K |
| CommonStock | 2.58K | 14.00 | 22.59K | 2.59K |
| PreferredStock | 13.00K | 1.00K | 1.00K | 100.00K |
| TotalLiabilitiesNetMinorityInterest | 7.06M | 6.14M | 7.62M | 1.99M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 744.72K | 587.76K | 685.26K | 1.90M |
| NonCurrentDeferredLiabilities | 0.00 | 48.73K | 43.03K | 0.00 |
| NonCurrentDeferredTaxesLiabilities | 0.00 | 48.73K | 43.03K | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 744.72K | 539.03K | 642.23K | 1.90M |
| LongTermCapitalLeaseObligation | 744.72K | 539.03K | 642.23K | 0.00 |
| LongTermDebt | 1.90M | |||
| CurrentLiabilities | 6.31M | 5.55M | 6.93M | 91.23K |
| OtherCurrentLiabilities | 123.03K | |||
| CurrentDebtAndCapitalLeaseObligation | 207.76K | 118.67K | 123.03K | |
| CurrentCapitalLeaseObligation | 207.76K | 118.67K | 123.03K | 0.00 |
| CurrentDebt | 3.63M | |||
| OtherCurrentBorrowings | 3.63M | |||
| CurrentNotesPayable | 0.00 | |||
| PayablesAndAccruedExpenses | 6.11M | 5.43M | 6.81M | 91.23K |
| CurrentAccruedExpenses | 0.00 | 48.29K | ||
| InterestPayable | 0.00 | 48.29K | ||
| Payables | 6.11M | 5.43M | 6.81M | 42.94K |
| OtherPayable | 295.80K | 2.55M | 3.63M | |
| TotalTaxPayable | 268.28K | 299.87K | 373.19K | 0.00 |
| IncomeTaxPayable | 268.28K | 299.87K | 373.19K | 0.00 |
| AccountsPayable | 5.54M | 2.59M | 2.80M | 42.94K |
| TotalAssets | 30.56M | 27.35M | 29.24M | 2.20M |
| TotalNonCurrentAssets | 4.59M | 2.46M | 1.93M | 7.06K |
| NonCurrentDeferredAssets | 92.23K | 0.00 | ||
| NonCurrentDeferredTaxesAssets | 92.23K | 0.00 | ||
| GoodwillAndOtherIntangibleAssets | 3.02M | 1.44M | 776.86K | 0.00 |
| NetPPE | 1.48M | 1.01M | 1.15M | 7.06K |
| AccumulatedDepreciation | -336.53K | -190.00K | -83.81K | -64.02K |
| GrossPPE | 1.82M | 1.20M | 1.24M | 7.06K |
| Leases | 88.31K | 17.66K | 0.00 | |
| OtherProperties | 336.88K | 171.86K | 922.94K | 7.06K |
| MachineryFurnitureEquipment | 457.40K | 366.34K | 315.52K | 7.06K |
| BuildingsAndImprovements | 936.04K | 646.78K | ||
| Properties | 0.00 | 0.00 | 0.00 | |
| CurrentAssets | 25.97M | 24.89M | 27.31M | 2.20M |
| PrepaidAssets | 1.13M | 310.59K | 283.80K | 37.22K |
| Inventory | 11.28M | 5.73M | 3.29M | 105.65K |
| FinishedGoods | 11.28M | 5.73M | ||
| Receivables | 3.87M | 2.55M | 1.91M | 7.80K |
| AccountsReceivable | 3.87M | 2.55M | 1.91M | 7.80K |
| CashCashEquivalentsAndShortTermInvestments | 9.69M | 16.29M | 21.83M | 2.05M |
| CashAndCashEquivalents | 9.69M | 16.29M | 21.83M | 2.05M |
| CashFinancial | 9.69M | 16.29M | 21.83M | 2.05M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -14.85M | -9.56M | -5.55M | -1.83M |
| RepurchaseOfCapitalStock | -3.14M | -541.14K | -99.00K | 0.00 |
| RepaymentOfDebt | 0.00 | -1.90M | -475.32K | |
| IssuanceOfDebt | 0.00 | 3.38M | ||
| IssuanceOfCapitalStock | 8.52M | 4.09M | 30.37M | 0.00 |
| CapitalExpenditure | -2.32M | -788.10K | -305.00K | |
| InterestPaidSupplementalData | 8.13K | 0.00 | 48.29K | 38.12K |
| IncomeTaxPaidSupplementalData | 582.48K | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 9.69M | 16.29M | 21.83M | 2.05M |
| BeginningCashPosition | 16.29M | 21.83M | 2.05M | 989.89K |
| EffectOfExchangeRateChanges | -1.04M | 471.58K | 183.91K | -20.27K |
| ChangesInCash | -5.56M | -6.01M | 19.60M | 1.08M |
| FinancingCashFlow | 9.29M | 3.43M | 39.47M | 2.90M |
| CashFlowFromContinuingFinancingActivities | 9.29M | 3.43M | 39.47M | 2.90M |
| NetOtherFinancingCharges | -2.06M | |||
| ProceedsFromStockOptionExercised | 3.56M | 3.50K | 13.19M | 0.00 |
| NetPreferredStockIssuance | -99.00K | 0.00 | ||
| PreferredStockPayments | -99.00K | 0.00 | ||
| NetCommonStockIssuance | 5.38M | 3.55M | 30.27M | 0.00 |
| CommonStockPayments | -3.14M | -541.14K | -99.00K | |
| CommonStockIssuance | 8.52M | 4.09M | 30.37M | 0.00 |
| NetIssuancePaymentsOfDebt | 347.94K | -125.99K | -1.93M | 2.90M |
| NetLongTermDebtIssuance | 347.94K | -125.99K | -1.93M | 2.90M |
| LongTermDebtPayments | 0.00 | -1.90M | -475.32K | |
| LongTermDebtIssuance | 0.00 | 3.38M | ||
| InvestingCashFlow | -2.32M | -656.15K | -14.62M | 0.00 |
| CashFromDiscontinuedInvestingActivities | 0.00 | |||
| CashFlowFromContinuingInvestingActivities | -2.32M | -656.15K | -14.62M | 0.00 |
| NetBusinessPurchaseAndSale | 0.00 | -14.35M | 0.00 | |
| PurchaseOfBusiness | 0.00 | -14.35M | 0.00 | |
| NetIntangiblesPurchaseAndSale | -322.26K | -705.85K | -111.02K | 0.00 |
| PurchaseOfIntangibles | -322.26K | -705.85K | -111.02K | 0.00 |
| NetPPEPurchaseAndSale | -2.00M | 49.70K | -160.60K | 0.00 |
| SaleOfPPE | 131.95K | 33.38K | 0.00 | |
| PurchaseOfPPE | -2.00M | -82.25K | -193.98K | 0.00 |
| OperatingCashFlow | -12.53M | -8.78M | -5.25M | -1.83M |
| CashFlowFromContinuingOperatingActivities | -12.53M | -8.78M | -5.25M | -1.83M |
| ChangeInWorkingCapital | -5.38M | -4.42M | 3.15M | -108.80K |
| ChangeInPayablesAndAccruedExpense | 3.17M | -1.44M | 3.55M | 5.81K |
| ChangeInAccruedExpense | 0.00 | -48.29K | 23.97K | |
| ChangeInInterestPayable | 0.00 | -48.29K | 23.97K | |
| ChangeInPayable | 3.17M | -1.44M | 3.60M | -18.16K |
| ChangeInAccountPayable | 3.98M | -1.36M | 3.36M | -18.16K |
| ChangeInTaxPayable | -812.08K | -73.25K | 242.31K | 0.00 |
| ChangeInIncomeTaxPayable | -812.08K | -73.25K | 242.31K | 0.00 |
| ChangeInPrepaidAssets | -207.17K | -21.14K | 82.85K | -26.85K |
| ChangeInInventory | -6.01M | -2.37M | 42.98K | -81.88K |
| ChangeInReceivables | -2.34M | -594.14K | -524.49K | -5.88K |
| ChangesInAccountReceivables | -2.34M | -594.14K | -524.49K | -5.88K |
| OtherNonCashItems | -2.24M | -10.85K | 976.94K | |
| AssetImpairmentCharge | 0.00 | 18.33M | 0.00 | |
| DeferredTax | 0.00 | 0.00 | ||
| DeferredIncomeTax | 0.00 | 0.00 | ||
| DepreciationAmortizationDepletion | 223.53K | 149.15K | 25.16K | 12.74K |
| DepreciationAndAmortization | 223.53K | 149.15K | 25.16K | 12.74K |
| AmortizationCashFlow | 77.01K | 38.45K | ||
| AmortizationOfIntangibles | 77.01K | 38.45K | ||
| Depreciation | 146.52K | 110.70K | ||
| OperatingGainsLosses | 548.00 | 9.73M | ||
| NetForeignCurrencyExchangeGainLoss | 0.00 | 548.00 | -50.00 | |
| NetIncomeFromContinuingOperations | -5.13M | -4.51M | -26.74M | -12.44M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SBFM
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|